New Heat-Based Cancer Therapy Kills 70% of Cells in Lab Tests

A new cancer treatment combining chemotherapy with two heat-based therapies has shown striking results in lab tests. Researchers achieved a 70% cell death rate within 72 hours using this approach on breast cancer cells. The findings, published in Advanced NanoBiomed Research, suggest a potential way to reduce drug doses while increasing effectiveness. The study focused on a trimodal therapy, merging traditional chemotherapy with magnetic hyperthermia and near-infrared radiation. On their own, neither heat method can safely reach temperatures high enough to kill cancer cells. But when combined with doxorubicin—a common chemotherapy drug—the treatment became far more potent.

Malignant cells are known to be especially vulnerable to heat. By adding hyperthermia, the team found they could use lower doses of doxorubicin while still destroying tumour cells efficiently. This reduces the risk of widespread toxicity, a common issue with standard chemotherapy. While this research remains in early stages, global trials on similar trimodal approaches have already taken place. Institutions like MD Anderson Cancer Center and Memorial Sloan Kettering in the US have tested combinations of surgery, chemotherapy, and radiation for cancers such as bladder and esophageal. Results from phase II/III trials up to 2023 show improved survival rates and organ preservation, though toxicity remains a concern.

The in vitro study highlights a promising direction for cancer treatment, where heat-based methods could enhance drug effectiveness while cutting side effects. Further research will determine whether this approach can move from lab tests to clinical use. If successful, it may offer a less toxic alternative for patients undergoing chemotherapy.